Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
Most Trending
Newly approved by the FDA, Moderna and Pfizer's updated COVID vaccines are poised to reach global markets. Anticipated profits for these companies raise questions about their stock performance. Interestingly, this concern extends beyond just Moderna and Biontech, both of which rely heavily on their vaccines as their primary commercial product.
Moderna initially surged by 20% in early August when the new COVID wave emerged. However, subsequent to this rise, its stock experienced a minor dip before climbing back to the same price point following the approval of the updated product for market distribution. Despite these fluctuations, it's worth noting that Moderna's stock is currently trading at its lowest range since mid-2021, when the vaccine's effectiveness was first demonstrated.
Moderna has revised its 2023 vaccine revenue projections from $5 billion to a promising $6-8 billion. However, what truly captures the attention of the company's investors are its forthcoming RNA-based drugs and vaccines, anticipated to provide consistent, enduring revenue streams. Currently, the COVID vaccine serves as a lucrative cash generator, earmarked to fund the advancement of these innovative products.
At the onset of the pandemic wave, Biontech's stock surged by 25%, but subsequently experienced a decline. Interestingly, unlike Moderna, the approval of their updated vaccine didn't trigger a notable resurgence. The company currently holds a market value of $27 billion. The distinction between Biontech and Moderna lies in the revenue-sharing arrangement with Pfizer. While they have a share of the global vaccine market – the largest in the world – Biontech's slice is proportionally smaller. Furthermore, Biontech is actively progressing in the development of additional RNA-based products, and both companies are well-financed for these ambitious endeavors.
When the August wave began, Pfizer's stock enjoyed a 16% surge, but it has since retraced below its pre-wave levels. Pfizer's stock volatility isn't solely tied to the COVID-19 pandemic. On October 19, the European competition authority will decide on the approval of Pfizer's massive $43 billion acquisition deal with cancer company Seagen, potentially triggering a thorough investigation.
Within the COVID-19 sector, Pfizer investors are eyeing a relatively stable market for the drug paclovid, with the company anticipating around $8 billion in revenue from it. Pfizer also has plans to introduce non-COVID related products, yet its stock has returned to its pre-2021 event pricing.
Novavax stands out as an underperformer among the COVID-19 vaccine contenders. On one hand, it surprised the market by reaching the finish line in the vaccine development race, despite competing against larger and better-funded rivals, thanks to its unique mechanism. However, it consistently lagged behind in other aspects. The company grappled with production issues, and by the time they were resolved, the overall interest in the field had started to decline.
Novavax saw a modest uptick at the start of August following the release of positive vaccine efficacy results against new variants. However, it subsequently declined as it became evident that the company had arrived late to the scene.
Please note that the article should not be considered as investment advice or marketing, and it does not take into account the personal data and requirements of any individual. It is not a substitute for the reader's own judgment, and it should not be considered as advice or recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
Receive our Daily Alerts
Enter your email to receive daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
Trading signals and opportunities
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Find out what happening right now and get all the pieces of the puzzle on important data activity before the major news sources break the story and see what are the trends
FIND US ON
Receive our Daily Alerts
Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.